Merz Aesthetics, the world’s largest dedicated medical aesthetics business, today announced the presentation of data on its flagship product, Xeomin® (incobotulinumtoxinA) at TOXINS 2021, taking place as a virtual online event January 16 and 17.
“Although we will miss seeing everyone in person, we are looking forward to virtually participating in the TOXINS 2021 conference and sharing important updates and data on the latest developments for the clinical applications of Xeomin,” said Terri Phillips, M.D., Chief Medical Affairs Officer, Merz Aesthetics.
The following presentations will be shared virtually at the TOXINS meeting and are intended to enhance the exchange of scientific information. All associated abstracts will be published in an online supplemental issue of Toxicon, an interdisciplinary peer-reviewed journal on toxins, with open access for six months after the virtual conference.
PRESENTATIONS
- IncobotulinumtoxinA demonstrates safety and prolonged duration of effect in a dose-ranging study for glabellar lines, Martina Kerscher, Germany
- IncobotulinumtoxinA injection for sebum control, face lifting, and pore size improvement, Je-Young Park, South Korea
- Comparison of two IncobotulinumtoxinA injection techniques for treating axillary hyperhidrosis, Ada Trindade de Almeida, Brazil
- Evaluation of One21 technique with IncobotulinumtoxinA for treatment of forehead wrinkles, Carla Pecora, Brazil
- The One21 approach compared with standard 5-point strategy for treating glabellar lines with IncobotulinumtoxinA, Carla Pecora, Brazil
- Tailored eyebrow shape and positioning using IncobotulinumtoxinA injection in the upper face, Carla Pecora, Brazil
- A Randomized, open-label, evaluator-blinded trial on the use of IncobotulinumtoxinA for the treatment of masseteric hypertrophy: Post-therapy changes in three-dimensional volumetric analyses, Andreas Nikolis, Canada
- Decreased therapeutic effect over time amongst botulinum toxin type A agents, Rashid Kazerooni, United States
Presentations, either in the form of poster, slides or video, will be viewable by attendees in the Virtual Poster Hall for the duration of the meeting beginning on Saturday, January 16 until Sunday, January 17.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven and category-leading, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 110 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 52 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
PLEASE SEE BELOW FOR IMPORTANT SAFETY INFORMATION about XEOMIN®, INCLUDING BOXED WARNING, AND FULL PRESCRIBING INFORMATION AT XEOMINAESTHETIC.COM.
_________________________________________________________________________________
INDICATIONS AND USAGE
XEOMIN® (incobotulinumtoxinA) for injection, for intramuscular use is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines with corrugator and/or procerus muscle activity in adult patients.
IMPORTANT SAFETY INFORMATION
|
WARNING: DISTANT SPREAD OF TOXIN EFFECT See full prescribing information for complete BOXED WARNING. |
| The effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have underlying conditions that would predispose them to these symptoms. |
CONTRAINDICATIONS
Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea). If serious and/or immediate hypersensitivity reactions occur further injection of XEOMIN should be discontinued and appropriate medical therapy immediately instituted. XEOMIN is contraindicated in patients with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.
Use in patients with an infection at the injection site could lead to severe local or disseminated infection. XEOMIN is contraindicated in the presence of infection at the proposed injection site(s).
WARNINGS AND PRECAUTIONS
- The potency units of XEOMIN are specific to the preparation and assay method used and are not interchangeable with other preparations of botulinum toxin products. Therefore, Units of biological activity of XEOMIN cannot be compared to or converted into Units units of any other botulinum toxin products.
- Treatment with XEOMIN and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. When distant effects occur, additional respiratory muscles may be involved. Patients may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. Dysphagia may persist for several months, which may require use of a feeding tube. Aspiration may result from severe dysphagia [See BOXED WARNING].
- Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of XEOMIN.
- Glabellar Lines: Do not exceed the recommended dosage and frequency of administration of XEOMIN. In order to reduce the complication of ptosis the following steps should be taken:
- avoid injection near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes;
- corrugator injections should be placed at least 1 cm above the bony supraorbital ridge.
- XEOMIN contains human serum albumin. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD or vCJD have ever been reported for albumin.
ADVERSE REACTIONS
Glabellar Lines: The most commonly observed adverse reaction (incidence ≥ 2% of patients and greater than placebo) for XEOMIN was Headache (5.4%).
DRUG INTERACTIONS
Co-administration of XEOMIN and aminoglycoside or other agents interfering with neuromuscular transmission, (e.g., muscle relaxants), should only be performed with caution as these agents may potentiate the effect of the toxin.
Use of anticholinergic drugs after administration of XEOMIN may potentiate systemic anticholinergic effects. The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.
USE IN PREGNANCY
There are no adequate data on the developmental risk associated with the use of XEOMIN in pregnant women. XEOMIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
PEDIATRIC USE
Safety and effectiveness of XEOMIN in patients less than 18 years of age have not been established.
Copyright © 2019 Merz North America, Inc. All rights reserved.
_________________________________________________________________________________
Corporate Contact:
Alison Brown
Director, Global Corporate Communications
Merz Aesthetics
6501 Six Forks Road, Raleigh, NC 27615
(919) 302-3296
media@merz.com
Copyright © 2020 Merz Pharmaceuticals, LLC. All rights reserved.
MERZ AESTHETICS and XEOMIN are registered trademarks of Merz Pharma GmbH & Co. KGaA.